Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma

• Published in: Oncotarget Vol. 7; no. 3; pp. 2401 - 2416
• Main Authors: Ye, Qing, Xu-Monette, Zijun Y., Tzankov, Alexandar, Deng, Lijuan, Wang, Xiaoxiao, Manyam, Ganiraju C., Visco, Carlo, Montes-Moreno, Santiago, Zhang, Li, Dybkær, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W.L., van Krieken, J. Han, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J.M., Parsons, Ben M., Møller, Michael B., Piris, Miguel A., Winter, Jane N., Medeiros, L. Jeffrey, Hu, Shimin, Young, Ken H.
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 19.01.2016
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cyclophosphamide - therapeutic use; Disease-Free Survival; Doxorubicin - therapeutic use; Female; Humans; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - mortality; Male; Middle Aged; Prednisone - therapeutic use; Proto-Oncogene Proteins c-bcl-2 - genetics; Proto-Oncogene Proteins c-bcl-6 - genetics; Proto-Oncogene Proteins c-myc - genetics; Research Paper; Rituximab; Translocation, Genetic; Vincristine - therapeutic use; Young Adult; BCL2; diffuse large B-cell lymphoma; BCL6; MYC; double-hit

Double-hit B-cell lymphoma is a common designation for a group of tumors characterized by concurrent translocations of MYC and BCL2, BCL6, or other genes. The prognosis of concurrent MYC and BCL6 translocations is not well known. In this study, we assessed rearrangements and expression of MYC, BCL2...